ObjectiveTo evaluate the effect and safety of sorafenib in patients with advanced hepatocellular carcinoma(HCC). MethodsThe computer-based search in Pubmed, Embase, Science Citation Index, and Cochrane for phaseⅡandⅢclinical trial related to sorafeinib in advanced HCC were conducted. Data abstraction and quality assessment were conducted according to enrolled criteria. Meta-analysis was performed by REVMAN 5.2 version, evidence recommendation was conducted by GRADE 3.6 version, which classify evidence level into:extremely low quality evidence, low quality evidence, moderate quality evidence, and high quality evidence. ResultsFive studies were included, 4 randomization control trial(RCT), 1 prospective no-randomization control clinical trial. Meta-analysis indicated that overall survival, time to progression, and disease control rate in sorafenib treatment group were higher than those in control group(P < 0.05). In addition, the incidence of hand-foot skin reaction, rash/desquamation, hypertention, and dirrahea in soafeinib treatment group were higher than those in control group(P < 0.05). ConclusionSorafeinib can prolong the overall survival, time to progression, and disease control rate in patients with advanced HCC, but there is still no evidence that sorafenib can improve tumor response in these patients.